- Market Capitalization, $K 21,803,852
- Shares Outstanding, K 118,848
- Annual Sales, $ 492,850 K
- Annual Income, $ -858,280 K
- 60-Month Beta 1.22
- Price/Sales 45.90
- Price/Cash Flow N/A
- Price/Book 27.50
|Period||Period Low||Period High||Performance|
| || |
-14.32 (-7.24%)since 08/20/21
| || |
+6.57 (+3.71%)since 06/18/21
| || |
+51.20 (+38.71%)since 09/18/20
Alnylam (ALNY) submits a marketing authorization application to the EMA for vutrisiran to treat adult patients with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA)...
Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2027" which delivers detailed overview of the global RNAi technology market in terms of market segmentation by therapy...
--- Additional Analyses Showed Similar Improvements in Progression of Neuropathy and Quality of Life Measures with Vutrisiran Treatment Compared with Placebo, Regardless of Prior TTR Stabilizer Use -
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has achieved full patient enrollment in its HELIOS-B Phase 3 study of vutrisiran, an investigational...
Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021.
Alnylam (ALNY) delivered earnings and revenue surprises of -2.55% and 10.40%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Tuesday reported a loss of $189.6 million in its second quarter.
--a^' Advanced Vutrisiran with New Drug Application (NDA) Submission to the U.S. Food and Drug Administration (FDA) for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis (hATTR-PN); Received...
Let us take a look at four drug/biotech companies, LLY, AMGN, INCY and ALNY, which are gearing up for their earnings release.
|Etfmg Treatments Testing and Advancements ETF|
|Global X Genomics & Biotechnology ETF|
|Biotechnology Index NYSE ETF|
|Principal Healthcare Innovators Index|
|Vaneck Biotech ETF|
|3rd Resistance Point||193.29|
|2nd Resistance Point||190.73|
|1st Resistance Point||187.09|
|1st Support Level||180.89|
|2nd Support Level||178.33|
|3rd Support Level||174.69|